Lancet PsychiatryPub Date : 2026-08-12DOI: 10.1016/s2215-0366(26)00201-4
Alexander S Roth, Nolan B Ayers
{"title":"AI scribe functions in psychiatric practice: clinical oversight, consent, and regulation","authors":"Alexander S Roth, Nolan B Ayers","doi":"10.1016/s2215-0366(26)00201-4","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00201-4","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"3 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-12DOI: 10.1016/s2215-0366(26)00233-6
Tony Kirby
{"title":"Mark Rapaport—aiming to leave a better world than he found","authors":"Tony Kirby","doi":"10.1016/s2215-0366(26)00233-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00233-6","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"198 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01DOI: 10.1016/s2215-0366(26)00174-4
Stefan Leucht,Mathias Harrer,Susan Illing,Christos Christogiannis,René S Kahn,W Wolfgang Fleischhacker,Josef Priller,John M Davis,Dimitris Mavridis,Stephen Z Levine
{"title":"Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials.","authors":"Stefan Leucht,Mathias Harrer,Susan Illing,Christos Christogiannis,René S Kahn,W Wolfgang Fleischhacker,Josef Priller,John M Davis,Dimitris Mavridis,Stephen Z Levine","doi":"10.1016/s2215-0366(26)00174-4","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00174-4","url":null,"abstract":"BACKGROUNDThe temporal course of antipsychotic drug action in schizophrenia remains poorly understood. We aimed to explore how different symptom domains of schizophrenia improve over time. Such knowledge has important implications for treatment decisions and for understanding the mechanisms of action of antipsychotic drugs.METHODSWe analysed individual patient data from an existing repository comprising six antipsychotic drug trials of 6-12 months' duration in patients with acute schizophrenia (n=2079; 1328 [64%] men, 751 [36%] women; 1577 [76%] White, 502 [24%] non-White; mean age 34·72 years [range 16-73]). We used descriptive statistics to examine improvement trajectories across five PANSS symptom domains according to an established five-factor model (positive symptoms, negative symptoms, hostility and excitement, anxiety and depression, and cognitive and disorganisation). Time-to-response analyses were conducted using a threshold of at least 50% symptom reduction to define response within each domain. We used path analysis to explore whether improvements in negative, positive, and cognitive symptoms were mediated by changes in other symptom domains. People with lived experience were not involved in the project.FINDINGSAll five symptom domains showed substantial improvements during the first weeks of treatment, which slowly plateaued from week 15 onwards. While the factors improved in parallel, some improved more than others. Within the first 6 months, on average, hostility and excitability symptoms decreased by 76% (95% CI -80·5 to -71·1) from baseline, positive symptoms by 64% (-68·0 to -60·5), anxiety and depression symptoms by 57% (-61·2 to -53·2), cognitive and disorganisation symptoms by 61% (-64·0 to -57·2), and negative symptoms by 50% (-53·9 to -46·4). Median time to response adjusted for baseline symptom severity, age, and sex, was 3 weeks (95% CI 3 to 3, restricted mean survival time [RMST] 6·60, SE 0·20)) for hostility and excitement and 4 weeks for positive symptoms (4 to 4, RMST 7·76, SE 0·20) and anxiety and depression symptoms (4 to 4, RMST 8·71, SE 0·22), compared with 8 weeks for negative symptoms (6 to 9, RMST 12·45, SE 0·25) and cognitive and disorganisation symptoms (6 to 9, RMST 12·06, SE 0·25). Exploratory investigations using path analysis suggested that only a small proportion of the improvement in negative symptoms was mediated by improvements in cognitive and disorganisation and anxiety and depression domains.INTERPRETATIONClinicians should be aware of earlier attainment of substantial response of hostility and excitement, then positive symptoms, before substantial reductions in other domains. Treatment changes should not be made prematurely when negative and cognitive and disorganisation symptoms persist, as improvement in these domains lags behind. Researchers should consider these temporal patterns when investigating the mechanisms of action of antipsychotic drugs.FUNDINGNone.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"320 1","pages":"688-698"},"PeriodicalIF":64.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01Epub Date: 2026-06-18DOI: 10.1016/S2215-0366(26)00159-8
Mena Farag, Ying Hei Chu, Diego Kaski
{"title":"Communication, expectancy, and placebo response in clinical trial design.","authors":"Mena Farag, Ying Hei Chu, Diego Kaski","doi":"10.1016/S2215-0366(26)00159-8","DOIUrl":"10.1016/S2215-0366(26)00159-8","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"640"},"PeriodicalIF":21.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148279330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01Epub Date: 2026-05-26DOI: 10.1016/S2215-0366(26)00162-8
Chandrasen Yadav
{"title":"Kosmemophobia: a paradox of beauty and disgust.","authors":"Chandrasen Yadav","doi":"10.1016/S2215-0366(26)00162-8","DOIUrl":"10.1016/S2215-0366(26)00162-8","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"645-646"},"PeriodicalIF":21.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148036901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01DOI: 10.1016/s2215-0366(26)00204-x
The Lancet Psychiatry
{"title":"Investing in young people pays dividends.","authors":" The Lancet Psychiatry","doi":"10.1016/s2215-0366(26)00204-x","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00204-x","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"362 1","pages":"627"},"PeriodicalIF":64.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01DOI: 10.1016/s2215-0366(26)00172-0
Patrick Bach,Johan Franck,Jonas Hällgren,Härje Widing,Mika Gissler,Jeanette Westman
{"title":"Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.","authors":"Patrick Bach,Johan Franck,Jonas Hällgren,Härje Widing,Mika Gissler,Jeanette Westman","doi":"10.1016/s2215-0366(26)00172-0","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00172-0","url":null,"abstract":"BACKGROUNDEvidence suggests that GLP-1 receptor agonists might reduce substance use across different substance use disorders. However, data on substance use-related outcomes after GLP-1 discontinuation are absent. This study aimed to investigate the risk of alcohol and substance use-related hospitalisations during and after exposure to GLP-1 receptor agonists.METHODSThis within-individual observational study used Swedish registers to identify residents of Stockholm County with a first registered diagnosis of type 2 diabetes between Jan 1, 2005, and Dec 31, 2024 who had received GLP-1 receptor agonists and, for comparison, DPP-4 inhibitors. Active follow‑up started on Jan 1, 2015, or on the date of the first registered diabetes diagnosis, whichever occurred later. Patients were followed up until the end of the observation period (Dec 31, 2024). The main outcomes were hospitalisations related to alcohol use disorder and substance use disorder (which included the alcohol use disorder-related events). Fixed-effects Poisson regression models were used to estimate rate ratios (RRs) of hospitalisations, comparing periods of GLP-1 receptor agonist or DPP-4 inhibitor exposure and two post-exposure windows (days 1-182 and 183-364) with unexposed periods in the same individuals. People with lived experience were not involved in the study.FINDINGS167 026 individuals with type 2 diabetes (mean age 63·98 years [SD 13·77]; median age 65·00 years [IQR 55·00-74·00]; 96 133 [57·6%] males and 70 893 [42·4%] females) were included in the study. Ethnicity data were unavailable. 1559 (0·9%) individuals had at least one alcohol use disorder-related hospitalisation and 2008 (1·2%) had at least one substance use disorder-related hospitalisation. 41 109 (24·6%) individuals received GLP-1 receptor agonists during the study period, and 23 666 (14·2%) received DPP-4 inhibitors. 308 (0·7%) of those receiving GLP-1 receptor agonists had at least one alcohol-related hospitalisation during the observational period, and 444 (1·1%) had at least one substance use-related hospitalisation; 957 (66·1%) of the 1447 substance use disorder-related hospitalisations recorded in these 444 individuals were attributed to alcohol use disorder. GLP-1 exposure was associated with lower rates of hospitalisations related to alcohol use disorder (RR 0·55, 95% CI 0·43-0·70) and substance use disorder (0·61, 0·50-0·74) compared with unexposed periods for the same individuals. For individuals with alcohol use disorder, the association with hospitalisation rate reduction persisted during days 1-182 after discontinuation of GLP-1 receptor agonists (0·70, 0·50-0·98) but was no longer evident during days 183-364 after discontinuation (1·07, 0·71-1·63); for substance use disorder, there were no statistically significant associations with reduction after discontinuation of GLP-1 receptor agonists (days 1-182: 0·79, 0·61-1·02; days 183-364: 0·89, 0·63-1·26). DPP-4 inhibitors were not associated with consiste","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"37 1","pages":"669-677"},"PeriodicalIF":64.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-08-01DOI: 10.1016/s2215-0366(26)00198-7
Jack Wilson,Olivia Dobson,Andrew Langcake,Palkesh Mishra,Zachary Bryant,Janni Leung,Danielle Dawson,Myfanwy Graham,Maree Teesson,Tom P Freeman,Wayne Hall,Gary C K Chan,Emily Stockings
{"title":"Efficacy and safety of cannabinoids - Authors' reply.","authors":"Jack Wilson,Olivia Dobson,Andrew Langcake,Palkesh Mishra,Zachary Bryant,Janni Leung,Danielle Dawson,Myfanwy Graham,Maree Teesson,Tom P Freeman,Wayne Hall,Gary C K Chan,Emily Stockings","doi":"10.1016/s2215-0366(26)00198-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00198-7","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"54 1","pages":"642-643"},"PeriodicalIF":64.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}